Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2019 | MGUS pathology

Tarek H Mouhieddine • 13 Sep 2019
IMW 2019
Multiple Myeloma Rare Diseases Smoldering Myeloma

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, outlines the pathology and prognosis of monoclonal gammopathy of undetermined significance (MGUS) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Tarek H Mouhieddine

5:20
The evolution of clonal hematopoiesis and associated outcomes in multiple myeloma
Tarek H Mouhieddine • 9 Dec 2023
4:44
Investigating immune dynamics in multiple myeloma treated with talquetamab monotherapy
Tarek H Mouhieddine • 9 Dec 2023
2:19
Clonal hematopoiesis in patients with multiple myeloma
Tarek H Mouhieddine • 11 Dec 2021
2:22
Outcomes and management of patients with R/R myeloma who progress on bispecific antibodies
Tarek H Mouhieddine • 11 Dec 2021

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals